Biogen Reports Two-Year Data Showing Diranersen Slows Early Alzheimer's Decline
Source: Benzinga ·

Biogen Inc. (NASDAQ:BIIB) announced Tuesday that its investigational therapy diranersen slowed clinical decline at two years in people living with early Alzheimer’s disease, according to new Phase 2 CELIA study data. Presenters shared the Week 96 findings at the Clinical Trials o
Read the full story at Benzinga
Shared from the GodsView world desk: live wires next to a globe of flights, ships, fires, and quakes.